Management of Fever and Chills After LUMVOA Infusion
Immediately stop or slow the infusion rate, administer antihistamines (diphenhydramine 25-50 mg) and corticosteroids (methylprednisolone 100 mg IV or equivalent), and provide close monitoring for symptom resolution before considering resumption of the infusion at a slower rate. 1
Immediate Actions
This patient is experiencing an infusion reaction, which occurs in approximately 9% of LUMVOA patients and typically presents with fever, chills, headache, and fatigue 1. These reactions are usually mild to moderate in severity and respond well to standard management.
Step-by-Step Management Protocol:
1. Stop or Slow the Infusion Immediately
- If symptoms are mild (Grade 1/2): slow the infusion rate significantly
- If symptoms are moderate to severe: stop the infusion completely
- Do not resume until symptoms resolve 2
2. Administer Medications Beyond Acetaminophen:
- Antihistamine: Diphenhydramine 25-50 mg IV or oral (or cetirizine 10 mg oral) 2
- Corticosteroid: Methylprednisolone 100 mg IV or equivalent 2
- Continue acetaminophen 650-1000 mg as already given 2
3. Monitor Vital Signs Closely:
- Blood pressure (watch for transient increases) 1
- Temperature
- Respiratory status
- Heart rate
4. Once Symptoms Resolve:
- Resume infusion at half the previous rate 2
- Titrate slowly to tolerance
- Extend infusion time if needed (LUMVOA can be given over 45 minutes minimum) 1
Important Considerations
For Future Infusions: The FDA label specifically recommends that patients who experience an infusion reaction should receive premedication before subsequent infusions 1:
- Corticosteroids (methylprednisolone 100 mg IV)
- Antihistamines (diphenhydramine 25-50 mg)
- Antipyretics (acetaminophen 650-1000 mg)
- Administer 1 hour before the next infusion
Observation Period: After treating any infusion reaction, maintain observation for at least 1-2 hours after symptom resolution due to the risk of biphasic reactions 2. This is particularly important for more severe initial presentations.
Critical Pitfalls to Avoid
- Do not dismiss as simple drug fever: While drug fever exists as a phenomenon 3, 4, this temporal relationship (during/immediately after infusion) clearly indicates an infusion reaction requiring immediate intervention
- Do not continue the infusion at the same rate: This risks progression to more severe reactions
- Do not skip premedication for future doses: The evidence strongly supports premedication after any infusion reaction 2, 1
- Do not confuse with infection: These are typically non-infectious reactions, though infection should be ruled out if fever persists beyond expected timeframes
The key distinction: LUMVOA infusion reactions are managed similarly to other monoclonal antibody infusion reactions per ESMO guidelines [2-2], with the specific management detailed in the FDA label taking precedence 1.